This commissioning standard document supports commissioners in NHS England and NHS Improvement with the implementation of a standardised framework for the local commissioning of dental services for people with diabetes (type 1 and type 2) and people with non-diabetic hyperglycaemia (NDH)

Among patients with acute ischemic stroke and hyperglycemia, treatment with intensive vs standard glucose control for up to 72 hours did not result in a significant difference in favorable functional outcome at 90 days. These findings do not support using intensive glucose control in this setting (JAMA)

Given that black patients with type 2 diabetes were not well represented in CVSTs and such trials were underpowered to evaluate racial differences, it remains unclear whether GLP‐1RAs or SGLT‐2is would reduce cardiovascular risk in such patients, and additional studies targeting black patients are urgently needed (Diabetes, Obesity and Metabolism)

This study highlights that occurrence of a CVE in T2DM patients did not prime the prescription of glucose‐lowering medications provided with cardiovascular protective effects, even though glucose control remained poor. These data emphasize the need to optimize the therapeutic regimen of T2DM patients with established cardiovascular disease, according to updated guidelines (JAHA)

Less complex regimens for intensification following basal insulin may help reduce the time and healthcare resources required for intensification and address some of the challenges T2D patients face when intensifying to basal–bolus or basal with GLP-1 (Diabetes Therapy)

β‐cell function after intervention was similar in patients with insulin‐ and sitagliptin‐treated LADA, regardless of the strength of autoimmunity. Further, participants with low levels of GAD antibodies did not experience progressive deterioration of β‐cell function over a 21‐month period. Taken together, these findings could be useful for clinicians’ choices of treatment in people with LADA (Diabetes, Obesity and Metabolism)

Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated (NEJM)

This survey highlights the importance of measures beyond HbA1c, such as treatment simplification and TIR, and patient preference for adjunct therapies that help address unmet needs in type 1 diabetes treatment (Diabetes Technology and Therapeutics)

In participants not at HbA1c goal on a sub‐maximal dose of metformin, addition of sitagliptin at the time of metformin dose uptitration improved glycaemic response and HbA1c goal attainment, with similar safety and tolerability, compared to metformin uptitration alone (Diabetes, Obesity and Metabolism)

In patients with T2DM, intensification following A1c ≥7.0% on 2OADs was associated with a significant improvement in glycemic control. Patients intensified with insulin had a higher baseline A1c but greater A1c reduction than those intensified with a non‐insulin agent. However, A1c remained above 8.0% overall (Diabetes, Obesity and Metabolism)

Among insulin‐naïve adults with T2D, Gla‐300 was associated with significantly better HbA1c reductions (latest value during 90–180‐day follow‐up) and similar or improved hypoglycemia outcomes (3‐ and 6‐month follow‐up) than Gla‐100 (Diabetes, Obesity and Metabolism)

This pathway is endorsed by UK‐wide clinical and patient associations and we recommend that providers and commissioners use it to ensure the right individual with diabetes has access to the right technology in a timely way to help achieve better outcomes (Diabetic Medicine)

Despite intensification, most patients failed the glycaemic goal of HbA1c <7%. The reduction depended mainly on pre‐intensification HbA1c values, with small differences between drugs (Diabetes, Obesity and Metabolism)

Subscribe

Platinum Sponsors

Gold Sponsors

Silver Sponsors

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.